...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Great Presetation today

Interesting that they now list the value at $3.00 US per share.

I guess we will have to see what price the currently proposed raise is done at.

Anyway, J&J and Pfizer must be sniffing around.

 

bfw

Share
New Message
Please login to post a reply